Transcriptional control of antibiotic resistance: from basic mechanisms to drugs – TRANSBIOTIC
Antibiotic-resistant bacteria become a major threat for public health worldwide. Tuberculosis is responsible for ~1,5 million of deaths every year and the number of multi-drug resistant cases increases. Nosocomial infections are responsible for ~ 25 000 deaths a year in the Europe. Development of new therapeutics requires deep understanding of the molecular mechanisms conferring resistance. Bacterial RNA polymerase is an essential enzyme of gene expression and the proven target for clinical drugs. This project aims to uncover molecular mechanism by which RNA polymerase modify potency of the clinical drug fidaxomicin and to design novel, fidaxomicin-derived, antibacterial molecules.
Project coordination
Konstantin Brodolin (Institut de Recherche en Infectiologie de Montpellier)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partner
UP-CiTCoM-UMR8038 Cibles Thérapeutiques et Conception de Médicaments
IRIM Institut de Recherche en Infectiologie de Montpellier
ICSN Institut de Chimie des Substances Naturelles
Help of the ANR 496,069 euros
Beginning and duration of the scientific project:
December 2020
- 48 Months
